Brookline Capital Markets Weighs in on MRKR FY2028 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Equities research analysts at Brookline Capital Markets dropped their FY2028 earnings per share (EPS) estimates for shares of Marker Therapeutics in a research note issued on Saturday, August 15th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $1.42 for the year, down from their previous estimate of $1.44. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. Brookline Capital Markets also issued estimates for Marker Therapeutics’ FY2029 earnings at $4.90 EPS and FY2030 earnings at $14.05 EPS.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.16. Marker Therapeutics had a negative return on equity of 53.33% and a negative net margin of 343.03%.

Other equities analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings cut shares of Marker Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $10.00.

Marker Therapeutics Price Performance

Shares of NASDAQ MRKR opened at $1.16 on Tuesday. The stock has a fifty day moving average price of $1.32 and a 200 day moving average price of $1.42. Marker Therapeutics has a 1-year low of $0.81 and a 1-year high of $2.46. The company has a market cap of $19.34 million, a PE ratio of -2.83 and a beta of 1.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Marker Therapeutics by 41.8% in the first quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock worth $228,000 after acquiring an additional 51,644 shares in the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Marker Therapeutics during the 4th quarter worth $222,000. Geode Capital Management LLC boosted its position in shares of Marker Therapeutics by 35.3% during the 4th quarter. Geode Capital Management LLC now owns 130,344 shares of the company’s stock worth $194,000 after purchasing an additional 34,028 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the period. Finally, LPL Financial LLC grew its stake in shares of Marker Therapeutics by 41.7% during the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after purchasing an additional 24,500 shares during the period. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.